Skip to content

Markers of Severity (CD177,S100A8 &S100A12) in Sever Acute Respiratory Syndrome Coronavirus 2(SARS-COV-2) Patients

Markers of Severity in Covid 19 Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05201625
Enrollment
90
Registered
2022-01-21
Start date
2021-12-15
Completion date
2022-12-31
Last updated
2022-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

Patients infected with covid-19 have a series of clinical manifestations, including fever, cough, myalgia or fatigue, dyspnea, even acute respiratory distress syndrome (ARDS), acute cardiac injury and secondary infection, and a lot of sever patients had to been admitted to the intensive care unit (ICU) One of the hallmark of COVID 19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. besides the positive viral nucleic acid analysis and the representative pulmonary CT findings (bilateral distribution of patchy shadows and ground glass opacity), most individual patients showed the changes in several immunological and biological markers . CD177 which is one of the most clinically important neutrophil alloantigen because: i) it is a neutrophil-specific marker representative of neutrophil activation, ii) it was the most highly differentiated expressed gene in patients, and iii) the protein can be measured in the serum, making its use as a marker clinically applicable. It is expressed on neutrophils, neutrophilic metamyelocytes, and myelocytes . Given the contribution of the neutrophil activation pathway in the clustering of COVID-19 patients, neutrophil-activation features that could act as possible reliable markers of disease evolution.

Interventions

DIAGNOSTIC_TESTreal time PCR

real time PCR

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* COVID 19 hospitalized patients (diagnosed by RT-PCR)

Exclusion criteria

* Age below 18 years and above 80.

Design outcomes

Primary

MeasureTime frameDescription
Markers of severity(CD177) in Sever respiratory syndrome coronavirus 2 (SARS-COV-2) patientsone year\- Measuring gene expression for CD 177 by RT-PCR and also by ELISA. Measuring gene expression for CD 177 by RT-PCR and also by ELISA.
Markers of severity(S100A8&S100A12) in Sever respiratory syndrome coronavirus 2 (SARS-COV-2) patientsone yearMeasuring level of S100A8 and S100A12 by ELISA.

Countries

Egypt

Contacts

Primary Contactmai h hamed, assistant lecturer
maihamdy3535@gmail.com01009560474
Backup Contactabeer s mohamed, professor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026